|
Authors:
Padaro Essohana, Kueviakoe Irenee Messanh, Magnang Hezouwe , Layibo Yao , Mawussi koffi , Segbena Akuete Yvon., Togo
|
|
Abstract:
Objective: To describe the epidemiological, clinical and biological profile of the myeloproliferatives syndromes (MPS) in Campus Teaching Hospital of Lome (Togo) Patients and methods: This is a descriptive retrospective study of the records of patients followed from June 2003 to August 2015 is a period of 12 years. The search for the fusion protein BCR-ABL and / or JAK2 mutation was performed by RT-PCR in the hematology department of the Henri Mondor Hospital in Creteil (France). Results: Eighty-five patients of 3641 patients (or 2.33%) were received in consultation for MPS .63 (1.73%) for CML and 22 (0.60%) SMP Ph- (13 PV, 8 TE 1 SM). The annual prevalence of SMP is 7.08 new cases per year. For CML, the sex ratio is 1.42% with a middle age of 39.63 +- 15.06 (range 9 -80ans). 87.3% had splenomegaly. Hepatomegaly was present in 55.56% of patients. The mean leukocyte count was 204.93 +- 137.23 g / l (43.8 and 971 g / l). The mean hemoglobin level was 95.74 +- 18.83 g / l (51 and 138 g / l) and the mean platelet count was 4662.06 +-+-267,12G / L (108 and 1116 g / l). For PV, the average age was 46,7ans (31 to 65 years) a sex ratio of 2.25. The patient histories were mostly hypertension (53.8%). Headaches were the main clinical signs (69.2%). The V617F mutation of JAK2 is positive in 9 patients (69.2%). The average hematocrit, mean hemoglobin levels, average number of white cells and platelets in patients with JAK2 mutation positive and those with no mutation of JAK2 are respectively: 62.7 +- 4.4% (59, 0 +- 13.3%); 19,8g / l +- 4.4 d (17,9g / dl +-13.3); 9.8 g / l +-4.3 (7.5 g / l +- 4.2); 630,4G / l +-367.4 (441,0G / l +-564.7). In the TE, the annual prevalence of the disease is 0.66 new cases per year. The mean age was 48.4 +- 15.5 years (range 28 to 74) and a sex ratio of 0.33. The most identified clinical signs are headache (50%), paresthesia (50%). The JAK2 mutation was present in five patients (62.5%). In the presence of JAK2, the mean platelet count, hematocrit, hemoglobin and white blood cell counts were respectively 1618.2 G / L +- 402.7; 47.5% +- 15.9; 117g / L +- 42 and 11.2 g / L +- 5. As against those without the mutation JAK2, these values were respectively 1138G / L +- 570; 47.3% +- 15.3; 134g / L +- 10 and 7.6 g / L +- 1.4. Conclusion: The mutation was diagnosed JAK2V617F interest in polycythemia vera and can even be systematic sub-Saharan Africa.
|
